Under the terms of the five-year agreement, Akorn will be responsible for the manufacturing and supply of the two injectable products. Expected launch for both products is anticipated in the second half of 2008.
Arthur Przybyl, president and CEO of Akorn, said: “We are very pleased to have been selected as the contract manufacturer for these important hospital injectable products. We continue to seek contract pharmaceutical manufacturing opportunities in hospital injectables, ophthalmics and lyophilized products in order to expand this business.”